At Spyre, our aim is to develop novel therapies for gastrointestinal and rheumatological diseases built upon three validated approaches:
Engineering novel antibodies against validated targets
Incorporating the YTE-modification to prolong drug activity and reduce administration frequency, with potential for improved clinical outcomes through dose optimization and higher drug exposures
Developing rational drug combinations in simple high-concentration coformulations that may address distinct disease drivers and lead to superior efficacy and convenience
Together, if successful, we believe our approach will deliver new therapies to patients that have best-in-indication efficacy and convenience and represent a significant improvement over today’s standard of care